Bristol-myers Squibb Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BRISTOL-MYERS SQUIBB, and when can generic versions of BRISTOL-MYERS SQUIBB drugs launch?
BRISTOL-MYERS SQUIBB has one approved drug.
There are five US patents protecting BRISTOL-MYERS SQUIBB drugs.
There are eighty patent family members on BRISTOL-MYERS SQUIBB drugs in thirty-one countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Bristol-myers Squibb
International Patents: | 80 |
US Patents: | 5 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Patent Litigation for Bristol-myers Squibb: | See patent lawsuits for Bristol-myers Squibb |
PTAB Cases with Bristol-myers Squibb as patent owner: | See PTAB cases with Bristol-myers Squibb as patent owner |
Drugs and US Patents for Bristol-myers Squibb
International Patents for Bristol-myers Squibb Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 196813 | See Plans and Pricing |
Denmark | 3042901 | See Plans and Pricing |
Japan | 2010535785 | See Plans and Pricing |
Mexico | 2009001426 | See Plans and Pricing |
South Korea | 20100042641 | See Plans and Pricing |
Japan | 2015172064 | See Plans and Pricing |
Colombia | 6160327 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol-myers Squibb Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049522 | SPC/GB15/003 | United Kingdom | See Plans and Pricing | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826 |
2049522 | 300713 | Netherlands | See Plans and Pricing | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
2049522 | C300713 | Netherlands | See Plans and Pricing | PRODUCT NAME: DACLATASVIR EN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/939/001-004 20150119 |
2049522 | 122015000009 | Germany | See Plans and Pricing | PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822 |
2049522 | 211 50001-2015 | Slovakia | See Plans and Pricing | PRODUCT NAME: DAKLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939 - EU/1/14/939/004 20140826 |
2049522 | 2015/002 | Ireland | See Plans and Pricing | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/14/939/001-004 20140826 |
2049522 | PA2015006 | Lithuania | See Plans and Pricing | PRODUCT NAME: DACLATASVIRUM; REGISTRATION NO/DATE: EU/1/14/939/001 - EU/1/14/939/004 20140826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.